Methylation biomarkers for prostate cancer

Abstract

Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.

1 . A highly specific and highly selective method of detecting prostate cancer in a patient, comprising:
 obtaining a DNA sample from the patient; and   measuring, from the DNA sample, a methylation level in a regulatory region of each gene in a of a plurality of genes selected from the group consisting of: GSTP1, CYP27A1, CRYAB, EFS, GSTM2, NBL1, GPRC5B, WFDC2, FCGRT, VAT1, ITM2C, ID4, and C9orf125.   
     
     
         2 . The method of  claim 1 , further comprising comparing the measured methylation level for each of the plurality of genes to a respective threshold methylation level, and, based on the comparisons, detecting the presence or absence of prostate cancer in the patient with high sensitivity and high specificity. 
     
     
         3 . The method of  claim 1 , wherein the plurality of genes includes eight or more of the genes listed in  claim 1 . 
     
     
         4 . The method of  claim 1 , wherein the DNA sample is obtained from a body fluid, wherein the body fluid is blood, serum, plasma, saliva, urine, stool, tissue, or a combination thereof. 
     
     
         5 . The method of  claim 1 , wherein the genes are the genes of PC Set 1: GSTP1, CYP27A1, CRYAB, EFS, NBL1, GPRC5B, ID4, and C9orf125. 
     
     
         6 . The method of  claim 1 , wherein the genes are the genes of PC Set 2: GSTP1, CYP27A1, CRYAB, EFS, NBL1, VAT1, ID4, and C9orf125. 
     
     
         7 . The method of  claim 1 , wherein the genes are the genes of PC Set 3: GSTP1, CYP27A1, CRYAB, EFS, GPRC5B, WFDC2, ITM2C, and ID4. 
     
     
         8 . The method of  claim 1 , wherein the genes are the genes of PC Set 4: GSTP1, CYP27A1, CRYAB, EFS, GPRC5B, ITM2C, ID4 and C9orf125. 
     
     
         9 . The method of  claim 1 , wherein the genes are the genes of PC Set 5: GSTP1, CYP27A1, CRYAB, EFS, WFDC2, VAT1, ITM2C, and ID4. 
     
     
         10 . The method of  claim 1 , wherein the genes are the genes of PC Set 6: GSTP1, CYP27A1, CRYAB, EFS, VAT1, ITM2C, ID4, and C9orf125. 
     
     
         11 . The method of  claim 1 , wherein the genes are the genes of PC Set 7: GSTP1, CYP27A1, CRYAB, GPRC5B, VAT1, ITM2C, ID4, and C9orf125. 
     
     
         12 . The method of  claim 1 , wherein the genes are the genes of PC Set 8: GSTP1, CYP27A1, EFS, NBL1, GPRC5B, WFDC2, ID4, and C9orf125. 
     
     
         13 . The method of  claim 1 , wherein the genes are the genes of PC Set 9: GSTP1, CYP27A1, EFS, NBL1, WFDC2, VAT1, ID4, and C9orf125. 
     
     
         14 . The method of  claim 1 , wherein the genes are the genes of PC Set 10: GSTP1, CYP27A1, EFS, GPRC5B, WFDC2, ITM2C, ID4, and C9orf125. 
     
     
         15 . The method of  claim 1 , wherein the genes are the genes of PC Set 11: GSTP1, CYP27A1, EFS, WFDC2, VAT1, ITM2C, ID4, and C9orf125. 
     
     
         16 . The method of  claim 1 , wherein the genes are the genes of PC Set 12: GSTP1, CYP27A1, GPRC5B, WFDC2, VAT1, ITM2C, ID4, and C9orf125. 
     
     
         17 . The method of, wherein the genes are the genes of PC Set 13: CYP27A1, CRYAB, EFS, NBL1, GPRC5B, WFDC2, ITM2C, and ID4. 
     
     
         18 . The method of  claim 1 , wherein the genes are the genes of PC Set 14: CYP27A1, CRYAB, EFS, NBL1, WFDC2, VAT1, ITM2C, and ID4. 
     
     
         19 . The method of  claim 1 , wherein the genes are the genes of PC Set 15: CYP27A1, EFS, NBL1, GPRC5B, WFDC2, ITM2C, ID4 and C9orf125. 
     
     
         20 . The method of  claim 1 , wherein the genes are the genes of PC Set 16: CYP27A1, EFS, NBL1, WFDC2, VAT1, ITM2C, ID4, and C9orf125 or PC Set 17: CYP27A1, NBL1, GPRC5B, WFDC2, VAT1, ITM2C, ID4, and C9orf125. 
     
     
         21 . (canceled)